DAFNA Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

DAFNA Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$535K	Sell	111,859 -15,000	-12%	-$82.3K	0.12%	77
2025 Q4	$685K	Hold	126,859	–	–	0.16%	65
2025 Q3	$620K	Sell	126,859 -173,593	-58%	-$920K	0.15%	66
2025 Q2	$1.41M	Sell	300,452 -4,300	-1%	-$18K	0.39%	46
2025 Q1	$1.11M	Buy	304,752 +118,035	+63%	+$538K	0.32%	54
2024 Q4	$881K	Buy	186,717 +149,053	+396%	+$1.09M	0.22%	63
2024 Q3	$351K	Sell	37,664 -4,186	-10%	-$30.3K	0.08%	76
2024 Q2	$241K	Buy	+41,850	New	+$249K	0.06%	78

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

DAFNA Capital Management's FHTX Position: Q1 2026 in Review

DAFNA Capital Management reduced its Foghorn Therapeutics (FHTX) stake by 12% in Q1 2026, selling an estimated $82.3K and leaving 111,859 shares worth $535K. The position accounts for 0.12% of the portfolio, ranked #77.

DAFNA Capital Management first reported a position in FHTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.41M in Q2 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

DAFNA Capital Management held 111,859 shares of Foghorn Therapeutics worth $535K as of Q1 2026.
DAFNA Capital Management sold 15,000 Foghorn Therapeutics shares in Q1 2026, an estimated $82.3K.
Foghorn Therapeutics made up 0.12% of DAFNA Capital Management's portfolio in Q1 2026, its #77 holding.
DAFNA Capital Management first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 8 quarters since.
DAFNA Capital Management's Foghorn Therapeutics position peaked at $1.41M in Q2 2025.
105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.